A phase II trial of gefitinib in patients (pts) with progressive metastatic neuroendocrine tumors (NET): A Phase II Consortium (P2C) study.

@article{Hobday2006API,
  title={A phase II trial of gefitinib in patients (pts) with progressive metastatic neuroendocrine tumors (NET): A Phase II Consortium (P2C) study.},
  author={Timothy J. Hobday and Kyle D. Holen and Ross C. Donehower and John K. Camoriano and George P. Kim and Joel Picus and Philip Agop Philip and Ricardo Lloyd and Michelle R. Mahoney and Charles E Erlichman},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2006},
  volume={24 18_suppl},
  pages={4043}
}
4043 Background: Systemic treatment options for progressive metastatic NET, including islet cell carcinoma (ICC) and carcinoid tumor (CT), are limited. These tumors frequently express the epidermal growth factor receptor (EGFR). Gefitinib, a small-molecule inhibitor of the EGFR tyrosine kinase, has been shown to inhibit the growth of NET cell lines… CONTINUE READING